

Taiga Nishihori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3651083/publications.pdf>

Version: 2024-02-01

144
papers

3,787
citations

147726

31
h-index

168321

53
g-index

152
all docs

152
docs citations

152
times ranked

4902
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2022, 146, 485-493.	1.2	8
2	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	2.5	5
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	2.5	35
4	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Advances, 2022, 6, 259-269.	2.5	5
5	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37.	1.3	4
6	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood, 2022, 139, 1452-1468.	0.6	52
7	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8.	0.6	16
8	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298.	1.3	2
9	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	0.6	3
10	Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 185.e1-185.e7.	0.6	2
11	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338.	1.2	1
12	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Advances, 2022, 6, 3767-3778.	2.5	13
13	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	2.5	5
14	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. British Journal of Haematology, 2022, 198, 785-789.	1.2	2
15	Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. Transplantation and Cellular Therapy, 2022, , .	0.6	1
16	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances, 2022, 6, 3970-3973.	2.5	6
17	Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Medicine, 2021, 10, 1936-1943.	1.3	13
18	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Advances, 2021, 5, 975-983.	2.5	27

#	ARTICLE	IF	CITATIONS
19	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <i>Blood Advances</i> , 2021, 5, 1154-1163.	2.5	26
20	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
21	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 256.e1-256.e7.	0.6	12
22	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	0.6	85
23	Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 1683-1690.	1.3	12
24	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
25	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <i>Clinical Cancer Research</i> , 2021, 27, 2712-2722.	3.2	11
26	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 242.e1-242.e6.	0.6	5
27	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
28	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	0.6	137
29	Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 145-157.	1.2	12
30	Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 940-948.	0.6	20
31	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2897-2903.	1.3	10
32	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	0.6	65
33	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
34	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 768.e1-768.e6.	0.6	4
35	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury—Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	2.8	40
36	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. <i>Cancer Research</i> , 2020, 80, 5344-5354.	0.4	12
38	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	3.2	47
39	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
40	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3268-3276.	2.5	134
41	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	2.5	22
42	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
43	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	2.5	63
44	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1678-1687.	0.6	6
45	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
46	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
47	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
48	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	1.3	19
49	ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S112.	2.0	1
50	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.2	4
51	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
52	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
53	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
54	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89

#	ARTICLE	IF	CITATIONS
55	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
56	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
57	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	1.3	47
58	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
59	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , 2018, 67, 1-5.	0.4	14
60	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	1.3	1
61	Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. <i>British Journal of Haematology</i> , 2018, 180, 854-862.	1.2	9
62	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	1.3	75
63	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.	3.3	60
64	Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 307-314.	1.3	14
65	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 96-98.	0.6	5
66	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 400-405.	2.0	5
67	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.2	18
68	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
69	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	1.7	25
70	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
71	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	2.5	21
72	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	3.4	97

#	ARTICLE	IF	CITATIONS
73	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
74	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	1.7	33
75	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	2.0	65
76	Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. <i>Bone Marrow Transplantation</i> , 2017, 52, 1003-1009.	1.3	17
77	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	1.2	56
78	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 753-758.	0.2	18
79	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.2	5
80	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicines</i> , 2017, 5, 60.	1.4	12
81	Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. <i>International Journal of Genomics</i> , 2017, 2017, 1-6.	0.8	5
82	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 802-814.	2.0	37
83	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. <i>Lancet Oncology</i> , 2016, 17, e1.	5.1	0
84	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
85	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
86	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
87	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , 2016, 8, 435-447.	1.0	28
88	Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 118-126.	1.2	11
89	Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 26-29.	0.6	7
90	Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 291-294.	1.3	11

#	ARTICLE	IF	CITATIONS
91	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. <i>Blood</i> , 2016, 128, 3551-3551.	0.6	0
92	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	1.7	19
93	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. <i>Bone Marrow Transplantation</i> , 2015, 50, 1057-1062.	1.3	23
94	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14
95	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.2	8
96	Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. <i>Expert Review of Vaccines</i> , 2015, 14, 341-350.	2.0	14
97	Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. <i>Bone Marrow Transplantation</i> , 2015, 50, 1388-1392.	1.3	4
98	Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. <i>Bone Marrow Transplantation</i> , 2015, 50, 1487-1489.	1.3	5
99	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
100	Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. <i>Immunotherapy</i> , 2015, 7, 1059-1071.	1.0	8
101	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 5524-5524.	0.6	0
102	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. <i>Blood</i> , 2015, 126, 4493-4493.	0.6	0
103	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. <i>Blood</i> , 2015, 126, 4407-4407.	0.6	0
104	Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. <i>Bone Marrow Transplantation</i> , 2014, 49, 11-16.	1.3	10
105	Pretransplantation 5-Azacididine in High-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 776-780.	2.0	19
106	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
107	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	95
108	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	0.6	228

#	ARTICLE	IF	CITATIONS
109	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
110	Immunotherapy strategies for multiple myeloma: the present and the future. <i>Immunotherapy</i> , 2013, 5, 1005-1020.	1.0	4
111	Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1006-1012.	2.0	75
112	Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1144-1151.	2.0	15
113	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
114	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
115	Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1288-1300.	2.0	11
116	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013, 6, 2.	6.9	42
117	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	1.7	82
118	Bortezomib salvage followed by a phase II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. <i>British Journal of Haematology</i> , 2012, 157, 553-563.	1.2	21
119	Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 507-511.	0.2	37
120	Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 239-248.	2.0	28
121	ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1237-1244.	2.0	35
122	Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. <i>Haematologica</i> , 2011, 96, 1351-1356.	1.7	19
123	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. <i>International Journal of Hematology</i> , 2011, 93, 206-212.	0.7	15
124	Hepatobiliary manifestations of acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, e81-e83.	0.4	2
125	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. <i>Blood</i> , 2011, 118, 323-323.	0.6	1
126	A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. <i>Blood</i> , 2011, 118, 4158-4158.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 5142-5142.	0.6	1
128	Allogeneic Hematopoietic Cell Transplantation for Consolidation of VGPR or CR In Myeloma. <i>Blood</i> , 2011, 118, 4581-4581.	0.6	0
129	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBA±R) Using a Novel Principle of CD4-Guided Immune Suppression. <i>Blood</i> , 2011, 118, 3022-3022.	0.6	0
130	Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. <i>Blood</i> , 2011, 118, 1878-1878.	0.6	1
131	Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease. <i>Blood</i> , 2011, 118, 4548-4548.	0.6	0
132	Clinicohistologic Assessment of Bone Marrow Engraftment In Patients with Hematologic Malignancies Received Double Umbilical Cord Blood Transplantation – A Single Institutional Observation. <i>Blood</i> , 2011, 118, 4578-4578.	0.6	0
133	Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. <i>Blood</i> , 2011, 118, 3979-3979.	0.6	9
134	A Multidisciplinary Approach for Bone Metastases. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 346-347.	0.6	2
135	Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10-year experience at single institution. <i>American Journal of Hematology</i> , 2010, 85, 904-907.	2.0	3
136	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. <i>Journal of Hematology and Oncology</i> , 2010, 3, 36.	6.9	47
137	Relapsed and Refractory Multiple Myeloma. <i>Emerging Cancer Therapeutics</i> , 2010, 1, 383-402.	0.1	0
138	Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. <i>Annals of Transplantation</i> , 2010, 15, 21-9.	0.5	27
139	Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 362-365.	1.1	24
140	Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. <i>Clinical Colorectal Cancer</i> , 2008, 7, 260-266.	1.0	23
141	Accelerated fractionated radiation by concomitant boost (AFX-CB) with concurrent cis-platinum (CDDP) for advanced nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5540-5540.	0.8	0
142	Severe Action Tremor Related to Interferon-Alpha 2b Therapy for Malignant Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 526.	0.6	6
143	Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. <i>Journal of Neuro-Oncology</i> , 2002, 60, 177-183.	1.4	12
144	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. <i>The Cochrane Library</i> , 0, , .	1.5	0